Chordia Therapeutics (TSE:190A) Shares Outstanding (EOP): 73.73 Mil (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:190A Chordia Therapeutics Inc TSE:190A
11 GF Score
Price 円77.00
! 1 Warning Sign
View Full Analysis

What is Chordia Therapeutics Shares Outstanding (EOP)?

Chordia Therapeutics TSE:190A -2.53% 11 Shares Outstanding (EOP) is 73.73 Mil as of Feb. 2026. GuruFocus rates TSE:190A with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Chordia Therapeutics's shares outstanding for the quarter that ended in Feb. 2026 was 73.73 Mil.

Chordia Therapeutics's quarterly shares outstanding increased from Aug. 2025 (68.99 Mil) to Feb. 2026 (73.73 Mil). It means Chordia Therapeutics issued new shares from Aug. 2025 to Feb. 2026 .

Chordia Therapeutics's annual shares outstanding increased from Aug. 2024 (67.68 Mil) to Aug. 2025 (68.99 Mil). It means Chordia Therapeutics issued new shares from Aug. 2024 to Aug. 2025 .


Chordia Therapeutics  (TSE:190A) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Chordia Therapeutics Shares Outstanding (EOP) Related Terms


Chordia Therapeutics Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Chordia Therapeutics's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chordia Therapeutics Shares Outstanding (EOP) Chart

Chordia Therapeutics Annual Data
Trend Aug21 Aug22 Aug23 Aug24 Aug25
Shares Outstanding (EOP)
65.54 65.54 65.54 67.68 68.99

Chordia Therapeutics Semi-Annual Data
Aug21 Aug22 Aug23 Feb24 Aug24 Feb25 Aug25 Feb26
Shares Outstanding (EOP) Get a 7-Day Free Trial 65.54 67.68 68.99 68.99 73.73

TSE:190A vs VRTX, REGN, ALNY: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Chordia Therapeutics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chordia Therapeutics Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chordia Therapeutics's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Chordia Therapeutics's Shares Outstanding (EOP) falls into.


TSE:190A
11GF Score
Chordia Therapeutics Inc TSE:190A
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chordia Therapeutics Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 73.73 Mil mean?
Chordia Therapeutics (TSE:190A) has a Shares Outstanding (EOP) of 73.73 Mil as of Feb. 2026. The total shares a company has outstanding, at period-end. View historical data on Chordia Therapeutics and its competitors.
Is Chordia Therapeutics' Shares Outstanding (EOP) too high?
Chordia Therapeutics' current Shares Outstanding (EOP) is 73.73 Mil. Overall, Chordia Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Chordia Therapeutics' Shares Outstanding (EOP) compare to VRTX and REGN?
Chordia Therapeutics' Shares Outstanding (EOP) of 73.73 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Chordia Therapeutics and its competitors. Chordia Therapeutics's current Shares Outstanding (EOP) is 73.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chordia Therapeutics stock overvalued right now?
Chordia Therapeutics (TSE:190A) has a current Shares Outstanding (EOP) of 73.73 Mil. The current Shares Outstanding (EOP) is 73.73 Mil. Chordia Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Chordia Therapeutics (TSE:190A), the current Shares Outstanding (EOP) is 73.73 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chordia Therapeutics Business Description

Address 2-26-1 Muraoka-Higashi, Kanagawa, Fujisawa, JPN, 251-0012
Chordia Therapeutics Inc is a bio-venture company specializing in cancer research and development. Its mission is to deliver first-in-class cancer drugs to patients. It is a clinical-stage biotech company engaged in researching and developing novel therapies for cancers with high unmet medical needs.
11GF Score

Get the complete analysis for TSE:190A

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円77.00
Price